OXFORD, England, March 9, 2011 /PRNewswire-FirstCall/ -- Elsevier, the leading publisher of scientific, technical and medical information products and services, today announced that the Anxiety and Depression: 21st Neuropharmacology Annual Conference will take place in Virginia, USA on 10-11 November 2011 as a satellite to the 2011 Meeting of the Society for Neuroscience.
Anxiety and depression are amongst the most common brain disorders, with significant consequences for the individual and society. The 21st Neuropharmacology annual conference will bring together the leading experts in the field of psychiatry, neuroscience and pharmacology to present and discuss the latest research.
The scientific committee composed of acknowledged opinion leaders in anxiety and depression from across the spectrum of research areas will work alongside organizers from Elsevier to develop a multidisciplinary programme.
"The 21st Neuropharmacology Conference on Anxiety and Depression provides researchers with a marvelous opportunity to share knowledge and network with their peers," said Michael Osuch, executive publisher at Elsevier.
Among the topics covered at the Anxiety and Depression Conference are: - Emerging Therapeutic Targets in Depression - Emerging Therapeutic Targets in Anxiety - Animal Models - Genetics and Epigenetics in Depression and Anxiety - Imaging - Developmental Aspects of Anxiety and Depression - Neuronal Circuits Underlying Anxiety and Depression - Fear Extinction - Mechanism of Action of Antidepressants and Anxiolytics Attendees are welcome to register at: http://www.neuropharmacology-conference.elsevier.com About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell (http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/), Reaxys (https://www.reaxys.com/info/), MD Consult (http://www.mdconsult.com/) and Nursing Consult ( http://www.nursingconsult.com/), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review (http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC ( http://www.reedelsevier.com/), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact Francesca Webb +44(0)1865-843244 email@example.com